Penwest Pharmaceuticals Co (PPCO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
39 OLD RIDGEBURY ROAD DANBURY, CT 06810-5120

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Penwest Pharmaceuticals Co develops pharmaceutical products based on innovative proprietary oral drug delivery technologies. The foundation of the company's technology platform is TIMERx, an extended release delivery system that is adaptable to soluble and insoluble drugs.

Data derived from most recent annual or quarterly report
Market Cap 158.497 Million Shares Outstanding31.763 Million Avg 30-day Volume 28.654 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 0.0 / Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from PPCO instead.

View recent insider trading info

Funds Holding PPCO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PPCO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ENDO PHARMACEUTICALS HOLDINGS INC

WEST ACQUISITION CORP.

  • 10% Owner
33,627,009 2010-11-04 0

VANLENT ANNE

  • Director
No longer subject to file 2010-11-04 0

GOOD JENNIFER L PRESIDENT & CEO

  • Officer
No longer subject to file 2010-11-04 0

BAICHWAL ANAND SVP LICENSING & BD

  • Officer
No longer subject to file 2010-11-04 0

SCIASCIA THOMAS SVP CLIN DEV & REG AFF & CMO

  • Officer
No longer subject to file 2010-11-04 0

HAWI AMALE SVP, PHARMACEUTICAL DEV.

  • Officer
No longer subject to file 2010-11-04 0

MUSCOLO FRANK P CONTROLLER & CAO

  • Officer
No longer subject to file 2010-11-04 0

TANG KEVIN C

TANG CAPITAL MANAGEMENT LLC

TANG CAPITAL PARTNERS LP

  • 10% Owner
  • FORMER DIRECTOR
No longer subject to file 2010-09-20 0

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

PERCEPTIVE ADVISORS LLC

  • 10% Owner
No longer subject to file 2010-09-20 0

DRAKE PETER F

  • Director
No longer subject to file 2010-09-20 0

MEEKER DAVID P

  • Director
No longer subject to file 2010-09-20 0

WONG RODERICK

  • Director
No longer subject to file 2010-09-20 0

ZARRABIAN SAIID

  • Director
No longer subject to file 2010-09-20 0

LEMKEY JOHN G

  • Director
0 2010-06-30 0

FREIMAN PAUL E

  • Director
0 2010-01-04 0

BIANCHI CHRISTOPHE

  • Director
32,000 2010-01-04 0

PERCEPTIVE ADVISORS LLC

  • 10% Owner
0 2009-03-11 0

HAYES PAUL F VP, STRATEGIC MARKETING

  • Officer
0 2009-03-05 0

HENNESSEY ROBERT

  • Director
0 2009-01-02 0

STANIFORTH JOHN N

  • Director
84,048 2009-01-02 0

OSHEA WILLIAM J

  • Director
0 2009-01-02 0

EDELMAN JOSEPH

PERCEPTIVE ADVISORS LLC

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

  • 10% Owner
6,422,846 2008-10-24 0

PALLEIKO BENJAMIN L SVP, CORPORATE DEV. & CFO

  • Officer
0 2008-06-11 0

EDELMAN JOSEPH

PERCEPTIVE ADVISORS LLC

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

BRADLEY SCOTT

  • 10% Owner
6,296,046 2008-05-15 0

EDELMAN JOSEPH

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

PERCEPTIVE ADVISORS LLC

CHO MICHAEL

BRADLEY SCOTT

  • 10% Owner
24,905,500 2008-01-23 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments